Survey Highlights Negative Ways Acne and Acne Scars Can Affect Confidence
Ninety-nine percent of people would have more confidence if their acne and acne scars were gone, according to a new survey for Suneva Medical.
When it comes to skin issues, respondents feel that acne scars are worse than having acne, eczema, or rosacea. Nearly half of adults still have not outgrown their acne, and 48 percent withdraw from social outings and parties with friends because of their acne scars or facial blemishes, the survey showed.
Other survey findings include:
• 61 percent of those polled would wear less makeup if they were able to effectively treat acne scars and minimize the scarring
• Almost 50 percent of people with acne scars or blemishes don’t put photos onpne without heavy editing or filters
• 54 percent do not feel confident on a date because of their acne scars or facial blemishes
• 81 percent of respondents would select clear skin over keeping their fashion on trend, a nail manicure maintained, or maintaining a hairstyle that is rivaled by celebrities.
Kate Bosworth Partners with Allergan for Aczone Gel, 7.5% Launch
Actress, producer and model Kate Bosworth is the new face of Allergan plc’s Aczone (dapsone) Gel, 7.5%, a once-a-day prescription topical treatment for acne in patients 12 years of age and older. It was FDA approved in February 2016
Bosworth teamed up with New York City dermatologist and Practical Dermatology® editorial advisory board member Joshua Zeichner, MD to discuss the complexities of acne and acne care at a New York City media event.
“While one of my favorite parts of the job is being able to travel the world, my on-the-go schedule can encounter several inconsistencies, like lack of sleep or environmental changes,” Bosworth says in a news release. “Finding a balance with a healthy lifestyle and consistent skincare regimen has helped me tremendously. I visited my dermatologist and was prescribed Aczone Gel, 7.5% to treat my acne.”
Dermira’s Novel Facial Acne Treatment Shows Promise in Phase 2b Study
Topline results from a Phase 2b dose-ranging study show Dermira’s novel topical sebum inhibitor DRMO1 demonstrated statistically significant improvements in all primary endpoints compared to vehicle at the highest dose and in most primary endpoints at the two lower doses. In addition, DRM01 was well-tolerated with adverse events primarily mild or moderate in severity.
The initiation of the Phase 3 program is targeted for the first half of 2017, subject to an end-of-Phase 2 meeting with the FDA.
In the Phase 2b study, the primary endpoints were absolute changes from baseline in inflammatory and non-inflammatory lesion counts and the proportion of patients achieving at least a two-point improvement from baseline on the five-point Investigator’s Global Assessment (IGA) scale. Each endpoint was measured at the end of a 12-week treatment period.
Watch it Now
Interpreting the Data: Isotretinoin and Monthly Monitoring
By Hilary Baldwin MD, James Q. Del Rosso, DO, Neal Bhatia, MD, FAAD
In this edition of Derm Insider, host Neal Bhatia, MD talks to James Q. Del Rosso, DO and Hilary Baldwin, MD about a recent study suggesting monthly blood test monitoring for patients taking isotretinoin may not be necessary after two months if there is no abnormality. Drs. Del Rosso and Baldwin discuss the potential downside to this—from the outliers who may not show abnormalities until later to third-parties who could interpret the data to deny coverage for blood work dermatologists may still want to order. They also share insight into the pipeline for new rosacea and acne treatments.
Visit DermTube.com Search Key: Isotretinoin
DRM01 demonstrated statistically significant improvements from baseline to week 12 relative to vehicle in all primary efficacy endpoints at the highest dose of DRM01 (7.5% twice daily), which also demonstrated the highest efficacy in all primary endpoints compared to the two lower doses. The number of inflammatory lesions in patients treated with this highest dose of DRM01 was reduced by an average of 15.0 compared to 10.7 in patients in the combined vehicle group, or an average percentage reduction of 55.6 percent compared to 40.0 percent. The number of non-inflammatory lesions in patients treated with this same dose of DRM01 was reduced by an average of 17.5 compared to 9.3 in patients in the combined vehicle group, or an average percentage reduction of 47.8 percent compared to 28.7 percent. At the end of the 12-week treatment period, 25.9 percent of patients treated with this highest dose of DRM01 achieved a successful improvement in the IGA score (minimum two-grade improvement) compared to 9.8 percent of patients in the combined vehicle group.
Overall, a dose response was observed for all three primary endpoints. At the 4.0% once daily dose, DRM01 demonstrated statistically significant improvements in all three primary endpoints compared to the combined vehicle group. At the 7.5% once daily dose, DRM01 demonstrated statistically significant improvements in the inflammatory and non-inflammatory lesion count endpoints compared to the combined vehicle group, and approached statistical significance in the IGA improvement endpoint.
Based on the results, Dermira believes each of the three doses evaluated in the Phase 2b study could be a viable dose for a Phase 3 program. Further data analysis and an end-of-Phase 2 meeting with the FDA are expected to determine the precise dose and design for the Phase 3 program. n